| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | G3a; NG20; apo-M; HSPC336 |
| WB Predicted band size | 21 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human APOM |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于APOM(载脂蛋白M)抗体的相关文献摘要概括：
1. **文献名称**：*Apolipoprotein M modulates atherosclerotic plaque formation by affecting monocyte infiltration*
**作者**：Liu X. et al.
**摘要**：研究利用APOM基因敲除小鼠模型及APOM特异性抗体检测，发现APOM通过调节HDL功能抑制单核细胞向血管壁浸润，从而减缓动脉粥样硬化斑块的形成。
2. **文献名称**：*Apolipoprotein M promotes cholesterol efflux and inhibits inflammation via the S1P/S1PR1 pathway*
**作者**：Christoffersen C. et al.
**摘要**：通过APOM抗体免疫组化分析，揭示APOM通过介导鞘氨醇-1-磷酸(S1P)信号通路促进巨噬细胞胆固醇外流，并抑制炎症反应，提示其抗动脉粥样硬化的潜在机制。
3. **文献名称**：*Serum apolipoprotein M levels correlate with diabetic nephropathy progression*
**作者**：Zhang Y. et al.
**摘要**：采用ELISA法结合APOM抗体检测2型糖尿病患者血清APOM水平，发现其浓度与糖尿病肾病严重程度呈负相关，提示APOM可能作为该并发症的生物标志物。
(注：以上文献信息为基于公开研究的模拟概括，实际引用请核对具体文献原文。)
APOM (Apolipoprotein M) is a lipid-binding protein primarily associated with high-density lipoprotein (HDL), playing a critical role in cholesterol metabolism and inflammation regulation. Discovered in 1999. it is encoded by the APOM gene and structurally belongs to the lipocalin protein family. APOM facilitates the transport of sphingosine-1-phosphate (S1P), a bioactive lipid involved in endothelial function, immune response, and vascular integrity. Its interaction with HDL enhances S1P stability and bioavailability, linking APOM to anti-atherogenic and anti-inflammatory pathways.
APOM antibodies are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. They enable detection of APOM in tissues and biological fluids, aiding research into metabolic disorders like atherosclerosis, diabetes, and obesity. Studies using APOM antibodies have revealed reduced APOM levels in conditions such as acute coronary syndrome, chronic kidney disease, and sepsis, suggesting its potential as a biomarker. Additionally, these antibodies support investigations into APOM's role in cancer progression, where altered expression may influence tumor angiogenesis or metastasis.
Recent research focuses on APOM's therapeutic potential. Antibodies targeting APOM-S1P interactions are being explored for modulating inflammatory responses or improving HDL functionality. Challenges persist in fully elucidating APOM's molecular mechanisms, driving continued demand for high-specificity antibodies in structural and functional studies.
×
